India, Jan. 21 -- Sigachi Industries Ltd on Wednesday announced a major milestone in its research and development pipeline with the successful advancement of a Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor.
The development marks a significant step in the company's strategy to expand its footprint in complex, high-value specialty APIs, aligned with rising global demand for advanced therapies in rare and chronic disease segments. The global cystic fibrosis therapeutics market is estimated to be over USD 10 billion, driven by the adoption of next-generation modulator therapies, long-term treatment needs, and strong pricing resilience.
Sigachi said it is activel...